A Novel Cell Lysis Solution With Advantageous Use Characteristics For rAAV Manufacturing That Can Lead To Greater Downstream Recovery By Minimizing Upstream Loss

Delivering therapeutic DNA with recombinant adeno-associated virus (rAAV) can be challenging, particularly when aiming for high doses crucial for gene therapies and viral vaccines. While improving titer upstream is important, the true test lies in recovering that titer during harvest. This process is often hampered by the need to efficiently release rAAV particles from cells and separate them from cellular debris, a hurdle chemical lysis often struggles with despite its scalability.

Join Joe Gallagher, Technical Applications Manager at Avantor, as he discusses a novel cell lysis solution designed to rapidly rupture cell membranes, ensuring superior yield and titer of rAAV. Empower your manufacturing process with a more efficient and robust cell lysis strategy—click below to watch the full webinar.